<SEC-DOCUMENT>0001213900-26-054785-index.html : 20260512
<SEC-HEADER>0001213900-26-054785.hdr.sgml : 20260512
<ACCEPTANCE-DATETIME>20260512092747
ACCESSION NUMBER:		0001213900-26-054785
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260512
FILED AS OF DATE:		20260512
DATE AS OF CHANGE:		20260512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Clearmind Medicine Inc.
		CENTRAL INDEX KEY:			0001892500
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41557
		FILM NUMBER:		26966185

	BUSINESS ADDRESS:	
		STREET 1:		101-1220 WEST 6TH AVENUE
		CITY:			VANCOUVER, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V6H1A5
		BUSINESS PHONE:		972-54-5704749

	MAIL ADDRESS:	
		STREET 1:		101-1220 WEST 6TH AVENUE
		CITY:			VANCOUVER, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V6H1A5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0290311-6k_clearmind.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
Document 1 - file: ea0290311-6k_clearmind.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea029031102ex99-1.htm
<DESCRIPTION>PRESS RELEASE TITLED: "CLEARMIND MEDICINE REACHES IMPORTANT CLINICAL MILESTONE: 20 PARTICIPANTS NOW TREATED IN ONGOING PHASE I/IIA TRIAL OF CMND-100 FOR ALCOHOL USE DISORDER"
<TEXT>
Document 2 - file: ea029031102ex99-1.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea029031102_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 3 - file: ea029031102_ex99-1img1.jpg

</DOCUMENT>
</SEC-DOCUMENT>